作者: Fausto Rovelli , Claudio De Vita , Giorgio A Feruglio , Antonio Lotto , Aldo Selvini
DOI: 10.1016/S0735-1097(87)80426-6
关键词:
摘要: In the GISSI trial, 11,712 patients with acute myocardial infarction were randomized to receive either standard care or 1.5 million units streptokinase intravenously. A highly significant reduction in mortality during hospitalization streptokinase-treated was observed. The at 1 year determined 98.3% of who had been originally randomized; discharged alive similar those treated and not; that is, beneficial effects treatment on survival observed hospital phase study persisted unchanged comparable statistical significance for year. However, a higher incidence reinfarction occurred versus control groups both 6 month follow-up. Streptokinase no detectable effect history previous infarction.